comparemela.com

Ziping Wei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

/PRNewswire/ Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug.

Ziping weiPrnewswire bliss biopharmaceutical hangzhou co ltdEisai co ltdUnited nations sustainable development goals sdgsBliss biopharmaceutical hangzhou co ltdCo ltdWe improve human healthHuman epidermal growth factor receptorGreater chinaChief executive officerBliss biopharmaceuticalQiantang areaImprove humanCorporate conceptUnited nations sustainable development goalsBliss biopharmaceutical hangzhou co

Eisai Strikes Cancer Alliance to Line Up Potential Challenger to AstraZeneca Drug

Eisai gains an option to license a Bliss Biopharmaceutical drug that targets HER2, a cancer protein that has become a hot target for addressing several types of solid tumors. BlissBio could receive up to $2 billion in milestones and other payments.

United statesDaiichi sankyoZiping weiAmerican society of clinical oncologyBristol myers squibbAmerican association for cancer researchBliss biopharmaceuticalTokyo based eisaiAmerican associationAmerican societyDuality biologicsWeight lossMedical devicesHealthcare innovationMedcity newsMedcity news

vimarsana © 2020. All Rights Reserved.